A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy

A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy

The abnormal activation of epidermal growth factor receptor (EGFR) drives the development of non-small cell lung cancer (NSCLC). The EGFR-targeting tyrosine kinase inhibitor osimertinib is frequently used to clinically treat NSCLC and exhibits marked efficacy in patients with NSCLC who have an EGFR...

Full description

Bibliographic Details
Main Authors: Bin Xu, Fanjun Zeng, Jialong Deng, Lintong Yao, Shengbo Liu, Hengliang Hou, Yucheng Huang, Hongyuan Zhu, Shaowei Wu, Qiaxuan Li, Weijie Zhan, Hongrui Qiu, Huili Wang, Yundong Li, Xianzhu Yang, Ziyang Cao, Yu Zhang, Haiyu Zhou
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2023-09-01
Series:Bioactive Materials
Subjects:
Biomimetic nanoparticles
Membrane targeting
EGFR mutation
Tyrosine kinase inhibitor
Intracellular drug delivery
Clinical efficacy
Online Access:http://www.sciencedirect.com/science/article/pii/S2452199X23001238

Internet

http://www.sciencedirect.com/science/article/pii/S2452199X23001238

Similar Items